Tags

Type your tag names separated by a space and hit enter

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.
Eur J Contracept Reprod Health Care. 2011 Dec; 16(6):444-57.EJ

Abstract

OBJECTIVES

To compare the effects of a combined oral contraceptive (COC) containing nomegestrol acetate and 17β-oestradiol (NOMAC/E2) on haemostasis, lipids, carbohydrate metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG) with those of a COC containing levonorgestrel and ethinylestradiol (LNG/EE).

METHODS

In a randomised, open-label study, 121 healthy women, 18-50 years of age, were randomly assigned to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60) or LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61) for six cycles. The primary outcome was the change from baseline to cycle 6 for all indices.

RESULTS

All parameters were similar at baseline between the two groups. Over six cycles, NOMAC/E2 had less effect on most haemostatic indices than LNG/EE. Lipids were essentially unchanged with NOMAC/E2, whereas with LNG/EE high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides slightly increased. NOMAC/E2 induced negligible changes in glucose and insulin parameters, in contrast to LNG/EE. A much smaller increase in CRP was observed with NOMAC/E2 than with LNG/EE. NOMAC/E2 was associated with a greater increase in SHBG.

CONCLUSIONS

The monophasic COC NOMAC/E2 had less influence on haemostasis, lipids and carbohydrate metabolism than the COC LNG/EE.

Authors+Show Affiliations

FSHS Kuopio, Kuopio, Finland. ulla.agren@merck.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22066891

Citation

Ågren, Ulla M., et al. "Effects of a Monophasic Combined Oral Contraceptive Containing Nomegestrol Acetate and 17β-oestradiol Compared With One Containing Levonorgestrel and Ethinylestradiol On Haemostasis, Lipids and Carbohydrate Metabolism." The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, vol. 16, no. 6, 2011, pp. 444-57.
Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16(6):444-57.
Ågren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M. L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011). Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, 16(6), 444-57. https://doi.org/10.3109/13625187.2011.604450
Ågren UM, et al. Effects of a Monophasic Combined Oral Contraceptive Containing Nomegestrol Acetate and 17β-oestradiol Compared With One Containing Levonorgestrel and Ethinylestradiol On Haemostasis, Lipids and Carbohydrate Metabolism. Eur J Contracept Reprod Health Care. 2011;16(6):444-57. PubMed PMID: 22066891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. AU - Ågren,Ulla M, AU - Anttila,Marjatta, AU - Mäenpää-Liukko,Kristiina, AU - Rantala,Maija-Liisa, AU - Rautiainen,Hilkka, AU - Sommer,Werner F, AU - Mommers,Ellen, PY - 2011/11/10/entrez PY - 2011/11/10/pubmed PY - 2012/4/6/medline SP - 444 EP - 57 JF - The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception JO - Eur J Contracept Reprod Health Care VL - 16 IS - 6 N2 - OBJECTIVES: To compare the effects of a combined oral contraceptive (COC) containing nomegestrol acetate and 17β-oestradiol (NOMAC/E2) on haemostasis, lipids, carbohydrate metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG) with those of a COC containing levonorgestrel and ethinylestradiol (LNG/EE). METHODS: In a randomised, open-label study, 121 healthy women, 18-50 years of age, were randomly assigned to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60) or LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61) for six cycles. The primary outcome was the change from baseline to cycle 6 for all indices. RESULTS: All parameters were similar at baseline between the two groups. Over six cycles, NOMAC/E2 had less effect on most haemostatic indices than LNG/EE. Lipids were essentially unchanged with NOMAC/E2, whereas with LNG/EE high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides slightly increased. NOMAC/E2 induced negligible changes in glucose and insulin parameters, in contrast to LNG/EE. A much smaller increase in CRP was observed with NOMAC/E2 than with LNG/EE. NOMAC/E2 was associated with a greater increase in SHBG. CONCLUSIONS: The monophasic COC NOMAC/E2 had less influence on haemostasis, lipids and carbohydrate metabolism than the COC LNG/EE. SN - 1473-0782 UR - https://www.unboundmedicine.com/medline/citation/22066891/Effects_of_a_monophasic_combined_oral_contraceptive_containing_nomegestrol_acetate_and_17β_oestradiol_compared_with_one_containing_levonorgestrel_and_ethinylestradiol_on_haemostasis_lipids_and_carbohydrate_metabolism_ L2 - http://www.tandfonline.com/doi/full/10.3109/13625187.2011.604450 DB - PRIME DP - Unbound Medicine ER -